Amgen Shares Decline Following Late-Stage Trial Results for Sjögren's Disease Drug
Amgen (AMGN) experienced a decline in premarket trading following the release of topline data from its late-stage clinical trial for dazodalibep. The experimental therapy is designed to treat Sjögren's disease, an autoimmune condition. The market reaction reflects investor scrutiny regarding the detailed results provided by the California-based pharmaceutical company. While the specific efficacy metrics were part of the announcement, the immediate impact was reflected in downward pressure on the stock price.
Tickers: $AMGN
Topics: biotechnology clinical trial results Sjögren's disease stock price movement